A Phase IIa Proof of Concept Study to Explore the Efficacy, Tolerability and Safety of Fosmidomycin Sodium When Administered With Piperaquine Tetraphosphate to Adults and Older Children With Acute Uncomplicated Plasmodium Falciparum Malaria

Trial Profile

A Phase IIa Proof of Concept Study to Explore the Efficacy, Tolerability and Safety of Fosmidomycin Sodium When Administered With Piperaquine Tetraphosphate to Adults and Older Children With Acute Uncomplicated Plasmodium Falciparum Malaria

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs Fosmidomycin (Primary) ; Piperaquine
  • Indications Falciparum malaria
  • Focus Proof of concept; Therapeutic Use
  • Acronyms FOSPIP
  • Sponsors Jomaa Pharma
  • Most Recent Events

    • 26 Dec 2017 Primary endpoint (Per protocol, PCR-corrected cure rate on Day 28) has been met as per the results published in the Clinical Infectious Diseases
    • 26 Dec 2017 Results assessing safety and efficacy published in the Clinical Infectious Diseases
    • 14 Nov 2016 According to Jomaa Pharma media release, scientific paper on this study was presented at the 65th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top